StockWatch: Sarepta CEO Defends Elevidys as Q4 Sales Fall Short

… FDA approval as a DMD treatment. That’s down 17% from $132 million in Q3 … GEN EdgeIndustry NewsNewsAdeno-associated virusDuchenne muscular …